Soleno Therapeutics Sued in Federal Securities Class Action Over DCCR Safety and Launch Claims

Overview

• City of Pontiac Police and Fire Retirement System v. Soleno Therapeutics, No. 26‑cv‑01979, is pending in the Northern District of California.
• The putative class covers purchases of Soleno securities from March 26, 2025 through November 4, 2025.
• The complaint alleges Soleno understated safety issues in its Phase 3 DCCR program, including fluid retention, which allegedly reduced the drug’s commercial viability.
• Key disclosures cited include a short‑seller report on August 15, 2025, a September 10, 2025 Form 8‑K reporting a patient death after taking DCCR, and a November 4, 2025 update noting launch disruptions.
• Law‑firm summaries report stock declines of roughly 12% after the August report, about 19% following the September 8‑K, and approximately 26%–27% on November 5, 2025.